A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
Khan, O A Gore, M Stone, J Greystoke, Alastair Burke, W Carmichael, J Watson, Amanda J McGown, Gail Thorncroft, Mary R
Khan, O A
Gore, M
Stone, J
Greystoke, Alastair
Burke, W
Carmichael, J
Watson, Amanda J
McGown, Gail
Thorncroft, Mary R
Citations
Altmetric:
Abstract
Poly adenosine diphosphate (ADP)-ribose polymerase (PARP) is essential in cellular processing of DNA damage via the base excision repair pathway (BER). The PARP inhibition can be directly cytotoxic to tumour cells and augments the anti-tumour effects of DNA-damaging agents. This study evaluated the optimally tolerated dose of olaparib (4-(3--4-fluorophenyl) methyl-1(2H)-one; AZD2281, KU0059436), a potent PARP inhibitor, with dacarbazine and assessed safety, toxicity, clinical pharmacokinetics and efficacy of combination treatment.
Description
Date
2011-03-01
Publisher
Keywords
Type
Article
Citation
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. 2011, 104 (5):750-5 Br. J. Cancer